期刊文献+

白血病抑制因子对非小细胞肺癌细胞增殖和侵袭的影响及其机制 被引量:1

Effect of Leukemia Inhibitory Factor on Proliferation and Invasion of Non-small Cell Lung Cancer Cells and Related Mechanism
下载PDF
导出
摘要 目的探讨非小细胞肺癌(NSCLC)中白血病抑制因子(leukemia inhibitory factor,LIF)对细胞增殖和侵袭的影响及其作用机制。方法采用荧光定量PCR和Western blot检测LIF在人NSCLC组织和癌旁组织中的表达;应用重组LIF因子处理非小细胞肺癌细胞系A549和Z793,MTT技术检测重组LIF因子对细胞增殖的影响;Transwell实验检测重组LIF因子对细胞侵袭的影响;Western blot检测重组LIF因子对肿瘤细胞中AKT/m TOR信号通路的影响。结果 LIF在肺癌组织中的表达水平较正常癌旁组织显著上调(P=0.0078)。重组LIF处理A549和Z793细胞后,肿瘤细胞增殖较对照组明显增加(P<0.01);肿瘤细胞的侵袭能力较对照组明显增强(P<0.01);AKT蛋白的磷酸化水平明显增加,且其下游底物m TOR的表达显著上调。结论 LIF在非小细胞肺癌中表达上调,并通过激活AKT/m TOR信号通路促进非小细胞肺癌细胞的增殖和侵袭。 Objective To explore the influence of leukemia inhibitory factor(LIF) on the proliferation and invasion of non-small cell lung cancer(NSCLC) cells.Methods The expression of LIF in human NSCLC tissues and adjacent tissues were detected by fluorescent quantitative PCR and Western blot.After NSCLC cell lines A549 and Z793 were treated with recombinant LIF,we detected cell proliferation by MTT assay,cell invasion by Transwell assay,and ATK/m TOR pathway by Western blot.Results LIF expression was higher in lung cancer tissues than that in the matched adjacent tissues(P=0.0078).After A549 and Z793 cell lines were treated with recombinant LIF,the tumor cells showed a significantly higher proliferation rate and invasiveness in vitro than those in control group(P<0.01); moreover,the phosphorylated AKT level was significantly elevated and the expression of mammalian target of rapamycin(m TOR),the AKT downstream targets,was obviously up-regulated.Conclusion LIF expression is significantly increased in NSCLC cells.In addition,the ectopic expression of LIF promotes cell proliferation and invasion via activating AKT/m TOR pathway.
作者 李浩 崔永
出处 《肿瘤防治研究》 CAS CSCD 北大核心 2015年第6期553-555,共3页 Cancer Research on Prevention and Treatment
关键词 白血病抑制因子 非小细胞肺癌 增殖 侵袭 AKT Leukemia inhibitory factor(LIF) Non-small cell lung cancer(NSCLC) Proliferation Invasion AKT
  • 相关文献

参考文献11

  • 1孙长江,张西志,陈勇.厄洛替尼治疗老年晚期非小细胞肺癌的疗效[J].南方医科大学学报,2012,32(12):1839-1840. 被引量:9
  • 2Kenta Matsushita,Shousaku Itoh,Shun Ikeda,Yumiko Yamamoto,Yukako Yamauchi,Mikako Hayashi.LIF/STAT3/SOCS3 Signaling Pathway in Murine Bone Marrow Stromal Cells Suppresses Osteoblast Differentiation[J]. J. Cell. Biochem. . 2014 (7)
  • 3Mayuri Tarasuk,Ornnuthchar Poungpair,Duangporn Ungsupravate,Kunan Bangphoomi,Wanpen Chaicumpa,Pa-Thai Yenchitsomanus.Human single-chain variable fragment antibody inhibits macrophage migrationinhibitory factor tautomerase activity[J]. International Journal of Molecular Medicine . 2014 (3)
  • 4Silke Kuphal,Susanne Wallner,Anja K. Bosserhoff.Impact of LIF (leukemia inhibitory factor) expression in malignant melanoma[J]. Experimental and Molecular Pathology . 2013 (2)
  • 5Yuqing Ge,Rubin Cheng,Yuhong Zhou,Jianping Shen,Laijun Peng,Xiaofeng Xu,Qun Dai,Pei Liu,Haibing Wang,Xiaoqiong Ma,Jia Jia,Zhe Chen.Cryptotanshinone induces cell cycle arrest and apoptosis of multidrug resistant human chronic myeloid leukemia cells by inhibiting the activity of eukaryotic initiation factor 4E[J]. Molecular and Cellular Biochemistry . 2012 (1)
  • 6Gao Wen,Xu Jing,Shu Yong-Qian.miRNA expression and its clinical implications for the prevention and diagnosis of non-small-cell lung cancer. Expert review of respiratory medicine . 2011
  • 7Antonicelli Alberto,Cafarotti Stefano,Indini Alice,Galli Alessio,Russo Andrea,Cesario Alfredo,Lococo Filippo Maria,Russo Patrizia,Mainini Alberto Franco,Bonifati Luca Giuseppe,Nosotti Mario,Santambrogio Luigi,Margaritora Stefano,Granone Pierl.EGFR-Targeted Therapy for Non-Small Cell Lung Cancer: Focus on EGFR Oncogenic Mutation. International journal of medical sciences . 2013
  • 8Kamohara H,Sakamoto K,Ishiko T,Mita S,Masuda Y,Abe T,Ogawa M.Human carcinoma cell lines produce biologically active leukemia inhibitory factor (LIF). Research communications in molecular pathology and pharmacology . 1994
  • 9Kim EY,Kim A,Kim SK,et al.Inhibition of mTORC1 induces loss of E-cadherin through AKT/GSK-3β signaling-mediated upregulation of E-cadherin repressor complexes in non-small cell lung cancer cells. Respiratory Research . 2014
  • 10Suman P,Malhotra SS,Gupta SK.LIF-STAT signaling and trophoblastbiology. JAKSTAT . 2013

二级参考文献15

  • 1Haura EB. Treatment of advanced non-small-cell lung cancer: a review of current randomized clinical trials and an examination of emerging therapies[J]. Cancer Control, 2001, 8(4): 326-36.
  • 2Shepard FA, Pereira JR, Ciuleanu T, et al, Erlotinib in previously treated non-smallcell lung cancer[J]. N Engl J Med, 2005, 353(2): 123-32.
  • 3Blume-Jensen P, Hunter T. Oncogenic kinase signalling[J]. Nature, 2001, 411(6835): 355-65.
  • 4Janmaat ML, Giaccone G. Small-molecule epidermal growth factor receptor tyrosine kinase inhibitors[J]. Oncologist, 2003, 8(6): 576-86.
  • 5Robinson DM, Keating GM, Perry CM. Erlotinib[J]. Am J Cancer, 2005, 4(4): 247-52.
  • 6Akita RW, Sliwkowski MX. Preclinical studies with erlotinib (Tarreva) [J]. Semin Oncol, 2003, 30(3 Suppl 7): 15-24.
  • 7Kurnar A, Petri ET, Halmos B, et al. Structure and clinical relevance of the epidermal growth factor receptor in human cancer[J]. J Clin Oncol, 2008, 26(10): 1742-51.
  • 8Eberhard D, Johnson BE, Amler LC, et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib[J]. J Clin Oncol. 2005.23(25): 5900-9.
  • 9Miller VA, Riely GJ, Zakowski MF, et al. Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib [J]. J Clin Oncol, 2008, 26(9): 1472-8.
  • 10Jackman DM, Yeap BY, Ni LM, et al. Phase II clinical trial of chemotherapy-naive patients>or70 years of age treated with erlotinib for advanced non-small-cell lung cancer[J]. J Clin Oncol, 2007, 25(7): 760-6.

共引文献8

同被引文献2

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部